Martin Shkreli, the disgraced former CEO of Retrophin currently serving a seven-year sentence for securities fraud and conspiracy, was hoping for a SCOTUS hail mary after multiple appeals fell flat. Turns out the court wasn’t interested in hearing Shkreli’s pleas
read moreNovartis’ Entresto, the clear-cut market leader in heart failure, has been soul-searching since its highly touted trial in an untreated population fell flat. Now, a surprise competitor has cropped up—but Merck and Bayer’s upstart could actually give Novartis a boost. More:
read moreWhile new multiple sclerosis drugs from Novartis, Merck KGaA and Biogen have hit the market this year, all bearing blockbuster hopes, one group of doctors wasn’t all that interested in them. Instead, a repurposed therapy not yet approved for MS
read moreRight on the heels of news that Amgen is laying off neuroscience R&D staff on the East Coast, the drugmaker disclosed it’s shedding 172 more jobs. This round of layoffs will mostly hit field-based employees across the U.S. but also
read moreThe 2020 competition has welcomed a strong start to entry numbers since launching in September. More: Entries well underway for the 2020 International Clinical Researcher of the Year Source: News
read moreThe Phase II trial results are “impressive” and “encouraging”. More: PureTech schizophrenia drug shows mid-stage promise Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals